Ariad Pharmaceuticals (NASDAQ:ARIA) has had a rough year, with the stock down over 60% on a variety of bad news for its primary drug Iclusig. More specifically, past issues with blood clots resulted in the drug being pulled from the market and then returned with stronger warnings about side effects.
Many investors remain committed to Ariad and Iclusig's strong efficacy, even with those safety issues now well known.
In the video below, from Where The Money Is health care analyst David Williamson lays out their argument for Ariad -- and health care analyst Michael Douglass counters with the bear argument and why investing in Ariad may be a mistake.
Even if Ariad has a great year, it may have serious trouble keeping up with this top stock.
Give us five minutes and we'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.